Kailera is clinical stage biotech company developing a portfolio of obesity assets including potential best-in-class injectable and oral therapeutics.

Obesity represents a large opportunity and despite early clinical and commercial successes, it remains an underpenetrated market. Kailera is developing multi-incretin agonist peptides and small molecules to further push weight loss or improve patient convenience. Its lead candidate, ribupatide (KAI-9531) —licensed from Jiangsu Hengrui Pharmaceuticals in China—is a dual GLP-1/GIP receptor agonist currently being evaluated in global Phase 3 clinical trials. An oral version is preparing for a Ph2 start in 2026.